Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
© 2022. The Author(s)..
Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlight its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Scientific reports - 12(2022), 1 vom: 23. Apr., Seite 6687 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Agrati, Chiara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Neutralizing |
|---|
| Anmerkungen: |
Date Completed 26.04.2022 Date Revised 13.12.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-022-07741-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339904593 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339904593 | ||
| 003 | DE-627 | ||
| 005 | 20231227130753.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-022-07741-z |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1225.xml |
| 035 | |a (DE-627)NLM339904593 | ||
| 035 | |a (NLM)35461335 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Agrati, Chiara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.04.2022 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a Vaccine is the main public health measure to reduce SARS-CoV-2 transmission and hospitalization, and a massive scientific effort worldwide resulted in the rapid development of effective vaccines. This work aimed to define the dynamics and persistence of humoral and cell-mediated immune response in Health Care Workers who received a two-dose BNT162b2-mRNA vaccination. Serological response was evaluated by quantifying anti-RBD and neutralizing antibodies while cell-mediated response was performed by a whole blood test quantifying Th1 cytokines (IFN-γ, TNF-α, IL-2) produced in response to Spike peptides. BNT162b2-mRNA vaccine induced both humoral and cell-mediated immune response against Spike in all HCW early after the second dose. After 12 weeks from vaccination, the titer of anti-RBD antibodies as well as their neutralization function decreased while the Spike-specific T-cells persisted at the same level as soon after vaccine boost. Of note, a correlation between cellular and humoral response persevered, suggesting the persistence of a coordinated immune response. The long lasting cell-mediated immune response after 3 months from vaccination highlight its importance in the maintaining of specific immunity able to expand again to fight eventual new antigen encountering | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines, Synthetic |2 NLM | |
| 650 | 7 | |a mRNA Vaccines |2 NLM | |
| 650 | 7 | |a BNT162 Vaccine |2 NLM | |
| 650 | 7 | |a N38TVC63NU |2 NLM | |
| 700 | 1 | |a Castilletti, Concetta |e verfasserin |4 aut | |
| 700 | 1 | |a Goletti, Delia |e verfasserin |4 aut | |
| 700 | 1 | |a Sacchi, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Bordoni, Veronica |e verfasserin |4 aut | |
| 700 | 1 | |a Mariotti, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Notari, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Matusali, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Meschi, Silvia |e verfasserin |4 aut | |
| 700 | 1 | |a Petrone, Linda |e verfasserin |4 aut | |
| 700 | 1 | |a Aiello, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Najafi Fard, Saeid |e verfasserin |4 aut | |
| 700 | 1 | |a Farroni, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Colavita, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Lapa, Daniele |e verfasserin |4 aut | |
| 700 | 1 | |a Leone, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Agresta, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Capobianchi, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Ippolito, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Vaia, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Puro, Vincenzo |e verfasserin |4 aut | |
| 700 | 0 | |a INMI COVID-19 Vaccine Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Cimini, Eleonora |e investigator |4 oth | |
| 700 | 1 | |a Tartaglia, Eleonora |e investigator |4 oth | |
| 700 | 1 | |a Casetti, Rita |e investigator |4 oth | |
| 700 | 1 | |a Grassi, Germana |e investigator |4 oth | |
| 700 | 1 | |a Cristofanelli, Flavia |e investigator |4 oth | |
| 700 | 1 | |a Capri, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Santoro, Annapaola |e investigator |4 oth | |
| 700 | 1 | |a Orchi, Nicoletta |e investigator |4 oth | |
| 700 | 1 | |a Bettini, Aurora |e investigator |4 oth | |
| 700 | 1 | |a Francalancia, Massimo |e investigator |4 oth | |
| 700 | 1 | |a Specchiarello, Eliana |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 12(2022), 1 vom: 23. Apr., Seite 6687 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:1 |g day:23 |g month:04 |g pages:6687 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-022-07741-z |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 1 |b 23 |c 04 |h 6687 | ||